Successful bleeding control of refractory hemothorax in two hemophilia A patients with high-titer inhibitors

Hemophilia A (HA) is an inherited bleeding disorder, resulting from factor VIII (FVIII) deficiency due to F8 gene defect. Whenever hemorrhage occurs in patients with HA, clotting factor concentrates (CFCs) replacement therapy should be administered for hemostasis. CFC replacement therapy becomes ineffective with the presence of antibodies against FVIII, which are the inhibitors in HA. This is a serious complication associated with a high risk of severe bleeding. Bleeding control for HA with inhibitors requires a bypassing agent therapy, such as activated recombinant factor VII (rFVIIa) or activated prothrombin complex concentrate (APCC).

Source: Pediatrics and Neonatology - April 20, 2020 Category: Perinatology & Neonatology Authors: Ting-Chih Lin, Shu-Huey Chen, Chung-Che Wu, Chia-Yau Chang Tags: Letter to the Editor Source Type: research